Clinical Trials Insight: 700036520
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2010
At a glance
- Drugs NP 61 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Neuropharm; Noscira
- 30 Mar 2010 Status changed from not yet recruiting to completed.
- 10 Mar 2009 Tolerability results have been reported in a Noscira media release.
- 22 Aug 2008 New trial record.